立体定向消融放疗治疗寡转移性癌症:前瞻性注册单臂观察研究
本研究基于英国国家医疗服务体系(NHS)的前瞻性注册单臂观察研究,纳入1422例实体癌伴颅外寡转移患者,接受立体定向消融放疗(SABR)。SABR与高总生存和低毒性相关,基于该研究入选标准,NHS England于2020年3月将SABR纳入寡转移性疾病治疗选项。
要点
- 基于本研究标准,NHS England于2020年3月资助SABR用于寡转移。
核心结论
- 在颅外寡转移癌症患者中,使用SABR与高总生存率和低毒性相关。
研究设计与样本
- 前瞻性、注册 based、单臂、观察性评估研究,由NHS England通过Commissioning through Evaluation scheme资助。
- 患者入组条件:年龄≥18岁、确诊原发性癌(排除血液恶性肿瘤)、1-3个颅外转移灶、原发肿瘤至转移的无病间期>6个月(同期结直肠肝转移除外)、WHO体能状态≤2、预期寿命至少6个月。
- SABR处方剂量24-60 Gy,分3-8次给予。
- 主要终点为SABR治疗开始后1年和2年总生存率。
主要发现
- 未报告治疗相关死亡。
临床怎么用
- 对于符合本研究入选标准的颅外寡转移实体癌患者,可考虑使用SABR,因其与高总生存和低毒性相关。
- 基于本研究的选择标准,NHS England已于2020年3月将SABR纳入寡转移性疾病患者的治疗选项。
局限性
- 本研究为单臂观察性研究,缺乏对照组。
- 原文指出需要3期随机对照试验确认这些发现,该试验正在进行中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Stereotactic ablative body radiotherapy (SABR) is increasingly being used to treat oligometastatic cancers, but high-level evidence to provide a basis for policy making is scarce. Additional evidence from a real-world setting is required. We present the results of a national study of patients with extracranial oligometastases undergoing SABR, representing the largest dataset, to our knowledge, on outcomes in this population so far. METHODS: In 2015, National Health Service (NHS) England launched a Commissioning through Evaluation scheme that funded a prospective, registry-based, single-arm, observational, evaluation study of patients with solid cancer and extracranial oligometastases treated with SABR. Prescribed doses ranged from 24-60 Gy administered in three to eight fractions. The study was done at 17 NHS radiotherapy centres in England. Patients were eligible for the scheme if aged 18 years or older with confirmed primary carcinoma (excluding haematological malignancies), one to three extracranial metastatic lesions, a disease-free interval from primary tumour development to metastases of longer than 6 months (with the exception of synchronous colorectal liver metastases), a WHO performance status of 2 or lower, and a life expectancy of at least 6 months. The primary outcome was overall survival at 1 year and 2 years from the start of SABR treatment. The study is now completed. FINDINGS: Between June 15, 2015, and Jan 30, 2019, 1422 patients were recruited from 17 hospitals in England. The median age of the patients was 69 years (IQR 62-76), and the most common primary tumour was prostate cancer (406 [28·6%] patients). Median follow-up was 13 months (IQR 6-23). Overall survival was 92·3% (95% CI 90·5-93·9) at 1 year and 79·2% (76·0-82·1) at 2 years. The most common grade 3 adverse event was fatigue (28 [2·0%] of 1422 patients) and the most common serious (grade 4) event was increased liver enzymes (nine [0·6%]). Notreatment-related deaths were reported. INTERPRETATION: In patients with extracranial oligometastatic cancer, use of SABR was associated with high overall survival and low toxicity. 'The study findings complement existing evidence from a randomised, phase 2 trial, and represent high-level, real-world evidence supporting the use of SABR in this patient cohort, with a phase 3 randomised, controlled trial to confirm these findings underway. Based on the selection criteria in this study, SABR was commissioned by NHS England in March, 2020, as a treatment option for patients with oligometastatic disease. FUNDING: NHS England Commissioning through Evaluation scheme.
引用
- Chalkidou A, Macmillan T, Grzeda MT, et al. Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol. 2021. PMID: 33387498. doi:10.1016/S1470-2045(20)30537-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。